Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

New agents for neuropsychiatric disorders reported in recent Actelion and Abbott patents

Oct. 29, 2008

Minster announces results from phase II trial of tonabersat for migraine with aura

Oct. 29, 2008

NeuroSearch initiates dosing in HART study of ACR-16 in Huntington's disease

Oct. 29, 2008

Novel analgesics described in a recent University of Tennessee patent

Oct. 28, 2008

Noscira to initiate phase II NP-12 study in Alzheimer's disease

Oct. 28, 2008

Schering-Plough's asenapine meets primary endpoint in schizophrenia relapse prevention trial

Oct. 28, 2008

New compounds for neurological disorders reported in recent patents

Oct. 28, 2008

CHMP adopts negative opinion on Cymbalta for the treatment of fibromyalgia

Oct. 27, 2008

Further clinical trials suspended for GRC-6211 in osteoarthritis pain

Oct. 27, 2008

EMEA issues positive opinion for Lunivia MAA in Europe

Oct. 27, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...